LANXESS Aktiengesellschaft (ETR:LXS)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.56B -32.0% |
| Revenue (ttm) | 5.45B -14.3% |
| Net Income | -661.00M |
| EPS | -7.66 |
| Shares Out | 86.35M |
| PE Ratio | n/a |
| Forward PE | 26.67 |
| Dividend | 0.10 (0.55%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | 312,505 |
| Average Volume | 705,153 |
| Open | 18.94 |
| Previous Close | 18.07 |
| Day's Range | 18.02 - 19.01 |
| 52-Week Range | 11.03 - 29.46 |
| Beta | 1.16 |
| RSI | 57.83 |
| Earnings Date | May 7, 2026 |
About ETR:LXS
LANXESS Aktiengesellschaft, a specialty chemicals company, engages in the development, manufacture, and marketing of chemical intermediates, additives, and consumer protection products worldwide. It operates through three segments: Consumer Protection, Specialty Additives, and Advanced Intermediates. The company provides material protection products; disinfectant, hygiene, and preservative solutions; flavors and fragrances; liquid purification technologies for the treatment of water and other liquids; and precursors and intermediates for the ag... [Read more]
Financial Performance
In 2025, ETR:LXS's revenue was 5.67 billion, a decrease of -10.89% compared to the previous year's 6.37 billion. Losses were -577.00 million, 226.0% more than in 2024.
Financial StatementsNews
LANXESS Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw a slow start but improved momentum in March, with Q2 expected to show strong sequential gains driven by both volume and pricing. Full-year guidance is maintained, supported by cost savings and positive segment trends, though geopolitical risks remain.
LANXESS Aktiengesellschaft Earnings Call Transcript: Q1 2026
Q1 2026 saw sales and EBITDA decline sharply year-over-year, but March brought improving demand and volumes. Full-year EBITDA guidance is maintained, with price increases underway and cost discipline in focus amid ongoing geopolitical and supply chain risks.
Lanxess Q1 Loss Widens, Sales Down; Sees Sequentially Higher Adj. EBITDA In Q2; Backs FY26 Outlook
(RTTNews) - German specialty chemicals company Lanxess AG (LNXSF.PK) reported Thursday wider net loss and weak adjusted EBITDA in its first quarter, hurt by lower revenues. The company noted that a pe...
EQS-PVR: LANXESS Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: LANXESS Aktiengesellschaft LANXESS Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of ...
LANXESS Aktiengesellschaft Earnings Call Transcript: Q4 2025
Full-year EBITDA met guidance at €510 million, with net debt reduced and strong liquidity maintained. 2026 outlook remains cautious amid geopolitical and market volatility, but cost savings and portfolio focus position the company for recovery if volumes improve.
LANXESS Aktiengesellschaft Earnings Call Transcript: Q4 2025
Sales and EBITDA declined sharply year-over-year amid weak demand, high energy costs, and Asian competition. Major divestments and cost-saving measures, including 550 job cuts, were implemented to strengthen the balance sheet and support future growth.
Lanxess shares plunge after Advent calls off Envalior stake deal
Lanxess shares were set for their worst day ever after the German specialty chemicals maker said the sale of its stake in plastics joint venture Envalior had been called off, one of the first deals ...
LANXESS Aktiengesellschaft Earnings Call Transcript: Q3 2025
LANXESS Aktiengesellschaft Transcript: Investor Update
A strategic exit process for a polymer JV stake has been initiated, with a fixed value mechanism based on historical EBITDA and a clear timeline for put options in 2026 and 2028. Proceeds will prioritize deleveraging, with potential for share buybacks. Contractual safeguards ensure a structured exit, with further upside possible if performance exceeds benchmarks.
LANXESS Aktiengesellschaft Earnings Call Transcript: Q2 2025
Q2 saw continued demand weakness, margin pressure from Chinese imports, and a drop in EBITDA, but strong working capital management led to positive free cash flow and reduced net debt. Guidance for 2025 was lowered, with recovery expected in 2026 as market conditions and government stimulus improve.
LANXESS Aktiengesellschaft Transcript: AGM 2025
Despite a challenging macroeconomic and geopolitical environment, earnings and cash flow improved, cost savings exceeded targets, and a stable dividend was proposed. Strategic focus shifted to specialty chemicals, with strong sustainability achievements and ongoing risk management amid global trade tensions.
LANXESS Aktiengesellschaft Earnings Call Transcript: Q1 2025
Q1 2025 saw a 32% EBITDA increase and segment-wide improvement, with Consumer Protection rebounding on agro demand. Guidance is maintained, but macro uncertainty and tariffs have shortened order cycles. Early urethane divestiture and a planned plant closure are set to support future profitability.
LANXESS Aktiengesellschaft Earnings Call Transcript: Q1 2025
Stable sales and a 32% rise in operating income were achieved in Q1 2025, supported by cost savings and portfolio streamlining. EBITDA guidance for the year is confirmed at €600–650 million, with a stronger Q2 expected despite ongoing market uncertainties.
LANXESS Aktiengesellschaft Earnings Call Transcript: Q4 2024
Profitability improved in 2024 due to cost savings and higher utilization, with EBITDA up 20% year-over-year. The company completed its portfolio shift to specialty chemicals and expects modest demand improvement and further deleveraging in 2025.
LANXESS Aktiengesellschaft Earnings Call Transcript: Q3 2024
Q3 2024 saw flat sales but strong volume and EBITDA growth, driven by cost controls and higher utilization. Advanced Intermediates and Additives rebounded, while Consumer Protection lagged due to Saltigo. Full-year EBITDA guidance is maintained despite macro headwinds.
LANXESS Aktiengesellschaft Earnings Call Transcript: Q2 2024
Q2 2024 saw a 69% year-over-year EBITDA increase, driven by cost-cutting and improved utilization, though market conditions remain soft. Guidance for 2024 is maintained, with further cash flow and profitability improvements targeted for 2025–2026.